Sosei Group unit says first subject dosed in Phase1 clinical study of novel selective muscarinic M4 agonist in development to treat major symptoms of Alzheimer's disease
Sept 1 (Reuters) - Sosei Group Corp <4565.T>:Says co's unit Heptares Therapeutics and Allergan announced that the first healthy subject has been dosed with the first-in-class, selective muscarinic M4 receptor agonist HTL0016878 in a Phase 1 clinical study .Says unit will receive $15 million milestone payment under a global R&D and commercialisation partnership announced in April 2016.
Latest Developments forSosei Group Corp
- Sosei Heptares Says Marketing Application For Asthma Therapy Has Been Filed With EMA
- Sosei Group Says Sosei Heptares To Get US$15 Mln Milestone Payment From Astrazeneca
- Sosei Group to advance clinical development in Japan of HTL0018318 in patients with Dementia with Lewy Bodies (DLB)
- Sosei Group to sell Chiba-based pharmaceutical unit for $3.5 mln